Table 1 Clinical and biological characteristics of 238 individuals who recovered from COVID-19 according to hospitalization, in 386 days after primary infection

Sex

 Male

57 (65.5%)

73 (48.3%)

2.03

1.18 – 3.50

0.010 *

 Female

30 (34.5%)

78 (51.7%)

1.00

–-

Ages (in years)

 18 to 45

14 (16.1%)

67 (44.4%)

1.00

–-

 < 0.001*

 46 to 59

37 (42.5%)

65 (43.0%)

2.72

1.35 – 5.50

  ≥ 60

36 (41.1%)

19 (12.6%)

9.07

4.07 – 20.19

Symptoms

 Fever

61 (70.1%)

74 (50.0%)

2.35

1.34 – 4.11

0.003*

 Cough

64 (73.6%)

72 (48.6%)

2.94

1.65 – 5.22

 < 0.001*

 Dyspnea

74 (85.1%)

46 (31.1%)

12.62

6.37 – 25.03

 < 0.001*

 No change in sense of smell

48 (55.2%)

49 (33.1%)

2.49

1.14 – 4.28

 < 0.001*

 Myalgia

40 (46.0%)

74 (50.0%)

0.85

0.50 – 1.45

0.551*

 Asthenia

45 (51.7%)

84 (56.8%)

0.82

0.48 – 1.39

0.454*

 Sore throat

11 (12.6%)

51 (34.5%)

0.28

0.13 – 0.56

 < 0.001*

 Diarrhea

18 (20.7%)

46 (31.1%)

0.58

0.31 – 1.08

0.084*

 Abdominal pains

10 (11.5%)

19 (12.8%)

0.88

0.39 – 1.99

0.762*

 Headache

28 (32.2%)

100 (67.6%)

0.23

0.13 – 0.40

 < 0.001*

No symptoms

0 (0.0)

11 (7.3%)

–-

–-

–-

Comorbidities

 SAH

59 (67.8%)

35 (23.8%)

6.74

3.74 – 12.15

 < 0.001*

 T2DM

33 (37.9%)

13 (8.8%)

6.30

3.08 – 12.88

 < 0.001*

 Obesity

38 (46.3%)

50 (36.2%)

1.52

0.87 – 2.64

0.139*

Oxygen therapy

 Non-invasive

69 (79.3%)

–-

–-

–-

–-

 Invasive mechanical ventilation

18 (20.7%)

–-

–-

–-

–-

Time in ICU

29 (33.3%)

–-

–-

–-

–-

Distribution of samples

 Up to 90 DASO

72 (48.6%)

75 (34.1%)

–-

–-

0.003*

 91 to 180 DASO

41 (27.7%)

58 (26.4%)

–-

–-

-

  > 180 DASO

35 (23.6%)

87 (39.5%)

–-

–-

-

Presence of IgG-S antibody

 Positive

145 (98.0%)

168 (76.4%)

11.22

3.40 – 37.07

 < 0.001*

 Negative

3 (2.0%)

39 (17.7%)

1.00

–-

 Undetermined

0 (0.0)

13 (5.9%)

**

**